__timestamp | Eli Lilly and Company | Novo Nordisk A/S |
---|---|---|
Tuesday, January 1, 2019 | 122369084370 | 915808743862.0308 |
Wednesday, January 1, 2020 | 153244924560 | 992801077492.3201 |
Friday, January 1, 2021 | 250521319860.00003 | 1681508787391.9998 |
Saturday, January 1, 2022 | 329891098240 | 2129286754102.3198 |
Sunday, January 1, 2023 | 526678270123.72 | 3139248089387.3394 |
In pursuit of knowledge
In the past five years, the pharmaceutical giants Novo Nordisk and Eli Lilly have shown remarkable growth in market capitalization. Novo Nordisk, a leader in diabetes care, has seen its market cap soar by over 240% from 2019 to 2023, reaching a staggering $3.1 trillion. Meanwhile, Eli Lilly, known for its innovative treatments, has experienced a 330% increase, culminating in a market cap of $524 billion by 2023.
This growth reflects the companies' strategic advancements and the increasing global demand for healthcare solutions. Novo Nordisk's dominance is evident, with its market cap consistently surpassing Eli Lilly's by a significant margin. As the healthcare industry continues to evolve, these companies are well-positioned to capitalize on emerging opportunities, driving further growth and innovation.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters